Biostem Technologies (BSEM) investor relations material

Strategic transformation and market positioning

• Transitioned from a wound-centric to a surgical-centric business model, reducing risk and volatility through diversification of revenue streams and payer mix.

• Expanded board with experienced leaders from healthcare, finance, and commercial sectors to align with new strategic direction.

• Uplisted to Nasdaq, enhancing access to institutional capital and credibility.

• Addressable market estimated at $26 billion, with significant opportunity in both wound care and surgical applications.

• Four GPO contracts now cover two-thirds of U.S. hospital beds, improving hospital channel access.

Product portfolio and clinical evidence

• Portfolio includes 10+ commercial products across dry, hydrated, and cryopreserved formats, with recent IP expansion and 8 new U.S. patents.

• Over 400 publications and 1.2 million product applications demonstrate clinical acceptance and real-world use.

• Randomized controlled trial data in diabetic and venous leg ulcers expected in 2026, with ongoing expansion of real-world evidence.

• Key opinion leaders and physician champions drive adoption and repeatable hospital sales.

• 510(k) clearance for key products enables stronger marketing claims and evidence-based selling.

Commercial execution and expansion

• Sales force includes 60+ representatives, with plans to grow direct team from 30 to 40 by year-end and expand geographic coverage.

• Commercial strategy focuses on "land and expand"—starting with physician champions and expanding within hospitals.

• Direct and independent sales models target strategic hospital clusters and federal accounts, optimizing cost structure.

• Integration of CRM and ERP systems supports scalable commercial operations.

• Expansion into new specialties such as urology and foot/ankle, supported by strong clinical data and favorable economics.